Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Cristina Ancona, Mario Airoldi, Gabriella Moretti, Corrado Ficorella, Valentina Arcangeli, Lucrezia Diodati, Alberto Zambelli, Antonio Febbraro, Daniele Generali, Mirco Pistelli, Ornella Garrone, Antonino Musolino, Patrizia Vici, Michela Maur, Lucia MentucciaNicla La Verde, Giulia Bianchi, Salvatore Artale, Livio Blasi, Matilde Piezzo, Francesco Atzori, Anna Turletti, Chiara Benedetto, Maria Concetta Cursano, Alessandra Fabi, Vittorio Gebbia, Antonio Schirone, Raffaella Palumbo, Antonella Ferzi, Antonio Frassoldati, Claudio Scavelli, Luca Clivio, Valter Torri, behalf of The EVA Study Group On behalf of The EVA Study Group

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Original languageEnglish
Pages (from-to)31877-31887
Number of pages11
JournalOncotarget
Volume9
Issue number61
DOIs
Publication statusPublished - Aug 1 2018

    Fingerprint

Keywords

  • Advanced breast cancer
  • Elderly
  • Everolimus
  • Exemestane
  • Hormone-receptor positive

ASJC Scopus subject areas

  • Oncology

Cite this

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., ... On behalf of The EVA Study Group, B. O. T. EVA. S. G. (2018). Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study. Oncotarget, 9(61), 31877-31887. https://doi.org/10.18632/oncotarget.25874